Rouan Retires as Board Chair at Navidea Biopharmaceuticals
20 September 2021 - - S. Kathryn Rouan, Ph.D. retired as chair of the board of US-based precision immunodiagnostic agents and immunotherapeutics developer Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB), and as a director, and Claudine Bruck, Ph.D. retired as a director of the company, on September 14, 2021, at a meeting of the board of directors of the company that followed the company's 2021 annual meeting of stockholders, the company said.

Both retirements were effective immediately.

Following the retirement of Dr. Rouan as chair, the board appointed Alexander L. Cappello and John K. Scott, Jr., who were both existing members of the board, as chair of the board and vice chair of the board, respectively.

Also effective September 14, 2021, the board appointed Cappello to the audit committee, and therefore the current members of the audit committee are Amit Bhalla (chair), Malcolm Witter and Cappello.

On the same date, the board appointed Messrs.

Cappello and Scott to the Compensation, Nominating and Governance Committee and appointed Witter as chair, and therefore, the current members of the CNG Committee are Witter (chair), Scott and Cappello.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

The company is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment.

Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages.

The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform.

Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the company's pipeline through global partnering and commercialization efforts.